EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions

Jeremy W Jacobs iD, Garrett S Booth iD, Sheharyar Raza, Landon M Clark, Ross M Fasano iD, Eleni Gavriilaki iD, Elizabeth A Abels iD, Thomas C Binns iD, Miriam Andrea Duque, Zoe K McQuilten iD, María Eva Mingot-Castellano iD, Bipin N Savani iD und 6 weitere

American Journal of Hematology · 2024-12 · 99 (12) · 2351-2366

DOI: 10.1002/ajh.27487 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 26.09.2024. Verfasst von Jeremy W Jacobs und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transfusion Medicine, Department of Pathology, Microbiology, & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, US…. Hauptthemen laut MEDLINE: Receptors, Fc, Histocompatibility Antigens Class I, Hematologic Diseases, Immunoglobulin G. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta and protects IgG from degradation. Numerous clinical trials are investigating therapeutic FcRn inhibition for various immune‐mediated neuromuscular and rheumatologic conditions; however, FcRn inhibition also represents a potential therapy for IgG‐mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, immune thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell/platelet alloimmunization). Current evidence derived from both in vitro and in vivo studies suggests that FcRn inhibitors effectively reduce total IgG levels without impacting its production or altering the levels of other immunoglobulin isotypes. Moreover, the risk of serious adverse events, including serious infections, appears to be lower than that seen with other commonly used immunomodulatory/immunosuppressive therapies, albeit in the setting of limited clinical trial data. Ultimately, additional clinical trials that include varied patient populations are required prior to incorporating these agents into standard treatment algorithms for most hematologic conditions. However, based on the pathophysiology of IgG‐mediated hematologic disorders and the mechanism of action of FcRn inhibitors, these agents may represent a future novel therapeutic strategy for patients with hematologic conditions caused by IgG antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, FcHistocompatibility Antigens Class IHematologic DiseasesImmunoglobulin GHumansAnimals

Substanzen

Receptors, FcFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin G

Autor:innen und Institutionen

  • Division of Transfusion Medicine, Department of Pathology, Microbiology, & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Canadian Blood Services, Medical Affairs and Innovation, Toronto, Ontario, Canada.
  • Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Department of Pathology and Laboratory Medicine, Center for Transfusion and Cellular Therapy, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, Georgia, USA.

ORCID-Profile: Jeremy W Jacobs, Garrett S Booth, Ross M Fasano, Eleni Gavriilaki, Elizabeth A Abels, Thomas C Binns, Zoe K McQuilten, María Eva Mingot-Castellano, Bipin N Savani, Deva Sharma, Minh-Ha Tran, Christopher A Tormey, Brian D Adkins

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Jacobs, J. W., Booth, G. S., Raza, S., Clark, L. M., Fasano, R. M., Gavriilaki, E., Abels, E. A., Binns, T. C., Duque, M. A., McQuilten, Z. K., Mingot-Castellano, M. E., Savani, B. N., Sharma, D., Tran, M. H., Tormey, C. A., Moise, K. J., Bloch, E. M., & Adkins, B. D. (2024). Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions. American Journal of Hematology, 99(12), 2351-2366. https://doi.org/10.1002/ajh.27487

Vancouver

Jacobs JW, Booth GS, Raza S, Clark LM, Fasano RM, Gavriilaki E, et al. Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions. American Journal of Hematology. 2024;99(12):2351-2366. doi:10.1002/ajh.27487

BibTeX
@article{Jacobs2024,
  author = {Jacobs, Jeremy W and Booth, Garrett S and Raza, Sheharyar and Clark, Landon M and Fasano, Ross M and Gavriilaki, Eleni and Abels, Elizabeth A and Binns, Thomas C and Duque, Miriam Andrea and McQuilten, Zoe K and Mingot-Castellano, María Eva and Savani, Bipin N and Sharma, Deva and Tran, Minh-Ha and Tormey, Christopher A and Moise, Kenneth J and Bloch, Evan M and Adkins, Brian D},
  title = {Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {12},
  pages = {2351--2366},
  doi = {10.1002/ajh.27487}
}
Kostenlos starten →